Biogen recently announced that it has made Paul McKenzie its new executive vice president of pharmaceutical operations and technology in order to lead the company’s worldwide technical developments and manufacturing supply.
McKenzie will assume his new duties on July 1 of this year. His direct supervisor will be CEO George Scangos.
McKenzie will serve as part of the management team; encourage organizational responsibility; handle technology development; promote asset management; sustain worldwide manufacturing; and lead quality, supply chain operations and engineering. In addition, he will be responsible for the construction and operation of the advanced biologics manufacturing facility based in Solothurn, Switzerland.
Previously, McKenzie was the senior vice president of the company’s Global Biologics Manufacturing and Technical Operations. In his new position, he replaces John Cox, who is now the CEO of a Biogen spin-off.
“With his extensive technical and development expertise, we believe Paul is ideally suited to lead the next phase of growth across Biogen’s development and manufacturing operations,” Scangos said. “He will play an essential role, building upon our tradition of world-class manufacturing while leading the development of next-generation capabilities to ensure global availability of our current and future therapies.”
